HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of necrolytic migratory erythema in glucagonoma syndrome.

Abstract
The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic alpha-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. Necrolytic migratory erythema may cause marked morbidity and is frequently misdiagnosed. A 42-year-old white woman with a 1 1/2-year history of refractory dermatitis (most severe on the lower extremities) had the glucagonoma syndrome. Her severe morbidity was markedly relieved with the administration of intravenous amino acids. This therapy was successful in controlling the necrolytic migratory erythema through recurrences after somatostatin (SMS 201-995), surgical debulking, and chemotherapy proved inadequate.
AuthorsM E Shepherd, S S Raimer, S K Tyring, E B Smith
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 25 Issue 5 Pt 2 Pg. 925-8 (Nov 1991) ISSN: 0190-9622 [Print] United States
PMID1761771 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Amino Acids
  • Glucagon
Topics
  • Adult
  • Amino Acids (administration & dosage)
  • Erythema (drug therapy, pathology)
  • Female
  • Glucagon (blood)
  • Glucagonoma (drug therapy, pathology)
  • Humans
  • Infusions, Intravenous
  • Leg Dermatoses (pathology)
  • Necrosis
  • Recurrence
  • Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: